Literature DB >> 17259493

Probe-to-bone test for diagnosing diabetic foot osteomyelitis: reliable or relic?

Lawrence A Lavery1, David G Armstrong, Edgar J G Peters, Benjamin A Lipsky.   

Abstract

OBJECTIVE: We sought to assess the accuracy of the probe-to-bone (PTB) test in diagnosing foot osteomyelitis in a cohort of diabetic patients with bone culture proven disease. RESEARCH DESIGN AND METHODS: In this 2-year longitudinal cohort study, we enrolled 1,666 consecutive diabetic individuals who underwent an initial standardized detailed foot assessment, followed by examinations at regular intervals. Patients were instructed to immediately come to the foot clinic if they developed a lower-extremity complication. For all patients with a lower-extremity wound, we compared the results of the PTB test with those of a culture of the affected bone. We called PTB positive if the bone or joint was palpable and defined osteomyelitis as a positive bone culture.
RESULTS: Over a mean of 27.2 months of follow-up, 247 patients developed a foot wound and 151 developed 199 foot infections. Osteomyelitis was found in 30 patients: 12% of those with a foot wound and 20% in those with a foot infection. When all wounds were considered, the PTB test was highly sensitive (0.87) and specific (0.91); the positive predictive value was only 0.57, but the negative predictive value was 0.98.
CONCLUSIONS: The PTB test, when used in a population of diabetic patients with a foot wound among whom the prevalence of osteomyelitis was 12%, had a relatively low positive predictive value, but a negative test may exclude the diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17259493     DOI: 10.2337/dc06-1572

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  31 in total

1.  (18)F-FDG PET and PET/CT for the diagnosis of diabetic foot osteomyelitis.

Authors:  N Papanas; A Zissimopoulos; E Maltezos
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

2.  Calcaneal Osteomyelitis Associated With a Severe Abscess.

Authors:  Ali Memis; Mesut Mutluoglu; Sinan Öztürk; Kemal Kara; Hakan Ay
Journal:  J Am Coll Clin Wound Spec       Date:  2016-03-14

Review 3.  Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions.

Authors:  Nicola Kavanagh; Emily J Ryan; Amro Widaa; Gillian Sexton; Jerome Fennell; Sadhbh O'Rourke; Kevin C Cahill; Cathal J Kearney; Fergal J O'Brien; Steven W Kerrigan
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

4.  [The infected diabetic foot].

Authors:  T Mittlmeier; P Haar
Journal:  Unfallchirurg       Date:  2011-03       Impact factor: 1.000

5.  Outcomes of Osteomyelitis in Patients Hospitalized With Diabetic Foot Infections.

Authors:  Dane K Wukich; Kimberlee B Hobizal; Tresa L Sambenedetto; Kristin Kirby; Bedda L Rosario
Journal:  Foot Ankle Int       Date:  2016-08-22       Impact factor: 2.827

Review 6.  Management of osteomyelitis of the foot in diabetes mellitus.

Authors:  Fran Game
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

7.  Validating the probe-to-bone test and other tests for diagnosing chronic osteomyelitis in the diabetic foot.

Authors:  Rosario Morales Lozano; Maria L González Fernández; David Martinez Hernández; Juan V Beneit Montesinos; Sagrario Guisado Jiménez; Maximo A Gonzalez Jurado
Journal:  Diabetes Care       Date:  2010-07-09       Impact factor: 19.112

Review 8.  Optimising antimicrobial therapy in diabetic foot infections.

Authors:  Nalini Rao; Benjamin A Lipsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Management of diabetic foot infections in an era of increasing microbial resistance.

Authors:  Sandra Bliss Nelson
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725

10.  Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis.

Authors:  Marie T Dinh; Cybele L Abad; Nasia Safdar
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.